OptiBiotix Health PLC Extension of terms for WellBiome (8651S)

TIDMOPTI

RNS Number : 8651S

OptiBiotix Health PLC

14 July 2020

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

Extension of terms for WellBiome(R) with Draco Ingredients GmbH

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high

choleste r ol, diabetes and skincare, a nn o unces it has extended the terms of its original distribution agreement with Draco Ingredients GmbH ("Draco") as announced on 19 December 2019.

The agreement extends the product range from the distribution of SlimBiome(R) to include WellBiome(R). The territory remain unchanged with distribution rights in Germany.

WellBiome(R) is a proprietary blend of prebiotic functional fibres, functional dietary fibres and mineral optimised for health and wellbeing by promoting the diversity of the gut microbiome. The functional ingredient was launched at the end of June 2020 (RNS: 29 June 2020) in response to commercial partners expressing strong interest for an ingredient that would expand the commercial opportunity beyond slimming and provide a solution

to the   Health & Wellness industry , a market estimated to be worth US$4.2 trillion in 2019. 

Andre Wittke, General Manager at Draco, commented: "The introduction of WellBiome(R) gives us the opportunity to extend our product portfolio of functional ingredients with scientifically proven benefits and increase the commercial opportunity. There is growing awareness of the link between gut health and general wellbeing in Germany and WellBiome(R) creates a 'ready for market' opportunity to access this growing health and wellbeing trend. "

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division , c o mmented: " We are pleased to announce the extension of terms for Draco . This agreement recognises Draco's success in building brand awareness for OptiBiotix's SlimBiome(R) trademark in Germany with the launch of the www.slimbiome.de website and early commercial success. The agreement extends terms to expand the commercial opportunity in the territory and is a second commercial step (RNS: 6 July 2020) in bringing OptiBiotix's new functional ingredient WellBiome(R) to global markets and building brand awareness."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                      Contact via Walbrook 
                                                                     below 
 
 Cairn Financial Advisers LLP (NOMAD)                   Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 finnCap (Broker)                                       Tel: [phone] 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 Walbrook PR Ltd                                        Mob: [phone] 
 Anna Dunphy 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEASXDFAXEEFA

(END) Dow Jones Newswires

July 14, 2020 02:00 ET (06:00 GMT)